InflaRx Announces Q2 2026 Earnings Release Date
InflaRx N.V. (Nasdaq: IFRX) announced that it will release its second-quarter financial and operating results for 2026 on August 6, 2026 before the market opens. The company is a biopharmaceutical firm focused on developing anti-inflammatory therapeutics targeting the complement system. It has two key programs: izicopan, an oral small molecule inhibitor of C5a-induced signaling being developed for ANCA-associated vasculitis and renal diseases; and vilobelimab, an intravenously administered monoclonal antibody that targets free C5a. InflaRx is evaluating regulatory pathways in Europe following the EMA's recommendation on Tavneos. The company plans to engage with regulators regarding both of its drug candidates.
Tickers: $IFRX
Topics: biopharmaceutical C5a inhibition clinical development